Perlecan is essential for cartilage and cephalic development

被引:397
作者
Arikawa-Hirasawa, E
Watanabe, H
Takami, H
Hassell, JR
Yamada, Y [1 ]
机构
[1] Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA
[2] Shriners Hosp Crippled Children, Tampa, FL 33612 USA
关键词
D O I
10.1038/15537
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Perlecan, a large, multi-domain, heparan sulfate proteoglycan originally identified in basement membrane, interacts with extracellular matrix proteins, growth factors and receptors, and influences cellular signalling. Perlecan is present in a variety of basement membranes and in other extracellular matrix structures. We have disrupted the gene encoding perlecan (Hspg2) in mice. Approximately 40% of Hspg2(-/-) mice died at embryonic day (E) 10.5 with defective cephalic development. The remaining Hspg2(-/-) mice died just after birth with skeletal dysplasia characterized by micromelia with broad and bowed long bones, narrow thorax and craniofacial abnormalities. Only 6% of Hspg2(-)mice developed both ex-encephaly and chondrodysplasia. Hspg2(-/-) cartilage showed severe disorganization of the columnar structures of chondrocytes and defective endochondral ossification. Hspg2(-/-) cartilage matrix contained reduced and disorganized collagen fibrils and glycosaminoglycans, suggesting that perlecan has an important role in matrix structure. In Hspg2(-/-) cartilage, proliferation of chondrocytes was reduced and the prehypertrophic zone was diminished. The abnormal phenotypes of the Hspg2(-/-) skeleton are similar to those of thanatophoric dysplasia (TD) type I, which is caused by activating mutations in FGFR3 (refs 7-9), and to those of Fgfr3 gain-of-function mice. Our findings suggest that these molecules affect similar signalling pathways.
引用
收藏
页码:354 / 358
页数:5
相关论文
共 33 条
  • [1] IMMUNOSTAINING OF SKELETAL AND CARDIAC-MUSCLE SURFACE-MEMBRANE WITH ANTIBODY AGAINST DUCHENNE MUSCULAR-DYSTROPHY PEPTIDE
    ARAHATA, K
    ISHIURA, S
    ISHIGURO, T
    TSUKAHARA, T
    SUHARA, Y
    EGUCHI, C
    ISHIHARA, T
    NONAKA, I
    OZAWA, E
    SUGITA, H
    [J]. NATURE, 1988, 333 (6176) : 861 - 863
  • [2] Mouse models for extracellular matrix diseases
    Aszódi, A
    Pfeifer, A
    Wendel, M
    Hiripi, L
    Fässler, R
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (3-4): : 238 - 252
  • [3] Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA
    Aviezer, D
    Iozzo, RV
    Noonan, DM
    Yayon, A
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (04) : 1938 - 1946
  • [4] PERLECAN, BASAL LAMINA PROTEOGLYCAN, PROMOTES BASIC FIBROBLAST GROWTH FACTOR-RECEPTOR BINDING, MITOGENESIS, AND ANGIOGENESIS
    AVIEZER, D
    HECHT, D
    SAFRAN, M
    EISINGER, M
    DAVID, G
    YAYON, A
    [J]. CELL, 1994, 79 (06) : 1005 - 1013
  • [5] Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein
    Chuang, PT
    McMahon, AP
    [J]. NATURE, 1999, 397 (6720) : 617 - 621
  • [6] Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3
    Colvin, JS
    Bohne, BA
    Harding, GW
    McEwen, DG
    Ornitz, DM
    [J]. NATURE GENETICS, 1996, 12 (04) : 390 - 397
  • [7] Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses
    Delezoide, AL
    LasselinBenoist, C
    LegeaiMallet, L
    Brice, P
    Senee, V
    Yayon, A
    Munnich, A
    Vekemans, M
    Bonaventure, J
    [J]. HUMAN MOLECULAR GENETICS, 1997, 6 (11) : 1899 - 1906
  • [8] Fibroblast growth factor receptor 3 is a negative regulator of bone growth
    Deng, CX
    WynshawBoris, A
    Zhou, F
    Kuo, A
    Leder, P
    [J]. CELL, 1996, 84 (06) : 911 - 921
  • [9] Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO
  • [10] 2-H